Skip to main content
. 2019 Feb 13;2019:5208092. doi: 10.1155/2019/5208092

Table 3.

Univariate analysis on features of eyes with IOFBs affecting BCVA (BCVA <1.3 logMAR and BCVA ≥0.5 logMAR).

Variables BCVA P value BCVA P value
<1.3 logMAR
no. (%)
≥1.3 logMAR
no. (%)
<0.5 logMAR
no. (%)
≥0.5 logMAR
no. (%)
Age (years)
 <18 7 (35.0) 13 (65.0) 0.020 8 (40.0) 12 (60.0) 0.002
 18∼50 101 (36.5) 176 (63.5) 169 (61.0) 108 (39.0)
 ≥50 41 (53.9) 35 (46.1) 59 (77.6) 17 (22.4)

Presenting VA
 <0.5 logMAR 140 (50.0) 140 (50.0) <0.001 221 (78.9) 59 (21.1) <0.001
 ≥0.5 logMAR 9 (9.7) 84 (90.3) 15 (16.1) 78 (83.9)

Length of wound
 0∼4 mm 77 (32.4) 161 (67.6) <0.001 126 (52.9) 112 (47.1) <0.001
 4∼10 mm 52 (49.5) 53 (50.5) 85 (81.0) 20 (19.0)
 10 mm or longer 20 (66.7) 10 (33.3) 25 (83.3) 5 (16.7)

Entry site of IOFBs
 I zone 108 (38.8) 170 (61.2) 0.395 172 (61.9) 106 (38.1) 0.612
 II zone 31 (47.0) 35 (53.0) 45 (68.2) 21 (31.8)
 III zone 10 (34.5) 19 (65.5) 19 (65.5) 10 (34.5)

Time before primary repair
 Self-sealing 37 (27.6) 97 (72.4) 0.001 68 (50.7) 66 (49.3) <0.001
 <24 h 95 (46.1) 111 (53.9) 141 (68.4) 65 (31.6)
 ≥24 h 17 (51.5) 16 (48.5) 27 (81.8) 6 (18.2)

Surface of IOFBs
 Small: <4 mm2 15 (30.0) 35 (70.0) <0.001 24 (48.0) 26 (52.0) <0.001
 Medium: 4∼16 mm2 103 (36.3) 181 (63.7) 176 (62.0) 108 (38.0)
 Large: >16 mm2 31 (79.5) 8 (20.5) 36 (92.3) 3 (7.7)

Multiple IOFBs
 Yes 15 (57.7) 11 (42.3) 0.055 19 (73.1) 7 (26.9) 0.282
 No 134 (38.6) 213 (61.4) 217 (62.5) 130 (37.5)

Magnetic of IOFBs
 Yes 118 (37.3) 198 (62.7) 0.016 193 (61.1) 123 (38.9) 0.038
 No 31 (54.4) 26 (45.6) 43 (75.4) 14 (24.6)

Location of IOFBs
 Anterior chamber 12 (25.0) 36 (75.0) 0.001 22 (45.8) 26 (54.2) <0.001
 Intralens 6 (22.2) 21 (77.8) 9 (33.3) 18 (66.7)
 Ciliary body 12 (66.7) 6 (33.3) 15 (83.3) 3 (16.7)
 Vitreous 59 (36.9) 101 (63.1) 102 (63.7) 58 (36.3)
 Retina 60 (50.0) 60 (50.0) 88 (73.3) 32 (26.7)

Time before IOFBs removal
 Within 24 h 77 (38.3) 124 (61.7) 0.675 122 (60.7) 79 (39.3) 0.427
 24∼72 h 30 (43.5) 39 (56.5) 51 (73.9) 18 (26.1)
 72 h∼1 week 20 (47.6) 22 (52.4) 25 (59.5) 17 (40.5)
 1∼2 weeks 6 (28.6) 15 (71.4) 14 (66.7) 7 (33.3)
 2 weeks∼1 month 9 (45.0) 11 (55.0) 13 (65.0) 7 (35.0)
 3 months or longer 7 (35.0) 13 (65.0) 11 (55.0) 9 (45.0)

Cataract
 Yes 128 (42.0) 177 (58.0) 0.091 205 (67.2) 100 (32.8) 0.001
 No 21 (30.9) 47 (69.1) 31 (45.6) 37 (54.4)

Vitreous hemorrhage
 Yes 90 (51.7) 84 (48.3) <0.001 138 (79.3) 36 (20.7) <0.001
 No 59 (29.6) 140 (70.4) 98 (49.2) 101 (50.8)

Retinal breaks
 Yes 70 (57.9) 51 (42.1) <0.001 100 (82.6) 21 (17.4) <0.001
 No 79 (31.3) 173 (68.7) 136 (54.0) 116 (46.0)

Retinal detachment
 Yes 42 (59.2) 29 (40.8) <0.001 58 (81.7) 13 (18.3) 0.001
 No 107 (35.4) 195 (64.6) 178 (58.9) 124 (41.1)

PVR
 Yes 34 (52.3) 31 (47.7) 0.025 58 (89.2) 7 (10.8) <0.001
 No 115 (37.3) 193 (62.7) 178 (57.8) 130 (42.2)
Endophthalmitis
 Yes 34 (61.8) 21 (38.2) <0.001 47 (85.5) 8 (14.5) 0.001
 No 115 (36.2) 203 (63.8) 189 (59.4) 129 (40.6)

Surgery approaches
 Magnet 50 (31.4) 109 (68.6) 0.001 87 (54.7) 72 (45.3) 0.002
 Vitrectomy 74 (51.4) 70 (48.6) 107 (74.3) 37 (25.7)
 Forceps or phaco 25 (35.7) 45 (64.3) 42 (60.0) 28 (40.0)

Multiple surgeries
 Yes 95 (46.1) 111 (53.9) 0.007 153 (74.3) 53 (25.7) <0.001
 No 54 (32.3) 113 (67.7) 83 (49.7) 84 (50.3)

Tamponade used
 Nonvitrectomy 74 (32.3) 155 (67.7) <0.001 128 (55.9) 101 (44.1) <0.001
 Gas implantation 29 (70.7) 12 (29.3) 33 (80.5) 8 (19.5)
 Silicone injection 28 (50.9) 27 (49.1) 46 (83.6) 9 (16.4)
 Balanced saline 18 (37.5) 30 (62.5) 29 (60.4) 19 (39.6)